Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directions
Z Megyesfalvi, CM Gay, H Popper… - CA: a cancer journal …, 2023 - Wiley Online Library
Small cell lung cancer (SCLC) is characterized by rapid growth and high metastatic capacity.
It has strong epidemiologic and biologic links to tobacco carcinogens. Although the majority …
It has strong epidemiologic and biologic links to tobacco carcinogens. Although the majority …
Overview of the 2022 WHO classification of neuroendocrine neoplasms
In this review, we detail the changes and the relevant features that are applied to
neuroendocrine neoplasms (NENs) in the 2022 WHO Classification of Endocrine and …
neuroendocrine neoplasms (NENs) in the 2022 WHO Classification of Endocrine and …
Small-cell lung cancer
Small-cell lung cancer (SCLC) represents about 15% of all lung cancers and is marked by
an exceptionally high proliferative rate, strong predilection for early metastasis and poor …
an exceptionally high proliferative rate, strong predilection for early metastasis and poor …
Chromatin profiles classify castration-resistant prostate cancers suggesting therapeutic targets
In castration-resistant prostate cancer (CRPC), the loss of androgen receptor (AR)
dependence leads to clinically aggressive tumors with few therapeutic options. We used …
dependence leads to clinically aggressive tumors with few therapeutic options. We used …
[HTML][HTML] Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer
Small cell lung cancer (SCLC) is an aggressive malignancy that includes subtypes defined
by differential expression of ASCL1, NEUROD1, and POU2F3 (SCLC-A,-N, and-P …
by differential expression of ASCL1, NEUROD1, and POU2F3 (SCLC-A,-N, and-P …
Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer …
JW Goldman, M Dvorkin, Y Chen, N Reinmuth… - The Lancet …, 2021 - thelancet.com
Background First-line durvalumab plus etoposide with either cisplatin or carboplatin
(platinum–etoposide) showed a significant improvement in overall survival versus platinum …
(platinum–etoposide) showed a significant improvement in overall survival versus platinum …
Ferroptosis, necroptosis, and pyroptosis in the tumor microenvironment: Perspectives for immunotherapy of SCLC
X Niu, L Chen, Y Li, Z Hu, F He - Seminars in Cancer Biology, 2022 - Elsevier
Small cell lung cancer (SCLC) is an aggressive form of lung cancer characterized by dismal
prognosis. Although SCLC may initially respond well to platinum-based chemotherapy, it …
prognosis. Although SCLC may initially respond well to platinum-based chemotherapy, it …
Radiotherapy in combination with CD47 blockade elicits a macrophage-mediated abscopal effect
Radiation therapy is a mainstay of cancer treatment but does not always lead to complete
tumor regression. Here we combine radiotherapy with blockade of the 'don't-eat-me'cell …
tumor regression. Here we combine radiotherapy with blockade of the 'don't-eat-me'cell …
The Hippo pathway in cancer: YAP/TAZ and TEAD as therapeutic targets in cancer
R Cunningham, CG Hansen - Clinical Science, 2022 - portlandpress.com
Tumorigenesis is a highly complex process, involving many interrelated and cross-acting
signalling pathways. One such pathway that has garnered much attention in the field of …
signalling pathways. One such pathway that has garnered much attention in the field of …
Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: randomized, double-blind, phase III KEYNOTE …
PURPOSE Pembrolizumab monotherapy has shown antitumor activity in patients with small-
cell lung cancer (SCLC). The randomized, double-blind, phase III KEYNOTE-604 study …
cell lung cancer (SCLC). The randomized, double-blind, phase III KEYNOTE-604 study …